Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)
The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) on 11 May 2022.
Adoption of income statement and balance sheet for the financial year 2021 and discharge from liability
The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2021 as well as the balance sheet and consolidated balance sheet as of 31 December 2021. The members of the board of directors and the managing director were discharged from liability for the financial year 2021.
Allocation of profit or loss
The AGM resolved, in accordance with the board of directors’ proposal, that no dividend shall be paid for 2021 and that the results of the company shall be carried forward.
Election of board members and auditors, and fees to the board of directors and auditors
The AGM resolved, in accordance with the nomination committee’s proposal, to re-elect Jacob Gunterberg, Heidi Hunter, Maarten Kraan, Sara Malcus and Hans Schikan as members of the board of directors for the period until the end of the next annual general meeting. Jacob Gunterberg was re-elected as the chairman of the board of directors. The audit firm EY AB was re-elected auditor of the company for the period until the end of the next annual general meeting.
The AGM further resolved on directors’ fees, including an additional fee subject to the board members’ acquisition of shares in Vicore Pharma, in accordance with the nomination committee’s proposal. The AGM further resolved, in accordance with the nomination committee’s proposal, that the fee to the auditor shall be paid as per approved statement of costs.
Guidelines on remuneration to members of group management
The AGM resolved, in accordance with the proposal from the board of directors, on guidelines for remuneration to members of group management. In short, the guidelines state that remuneration within Vicore Pharma shall be based on principles of performance, competitiveness and fairness and consist of fixed remuneration, variable remuneration, share and share price-related incentive programs, pension and other benefits. The guidelines do not apply to any remuneration decided or approved by the general meeting. The board of directors has reviewed the description of the company’s business in the remuneration guidelines and made a minor editorial change. No significant changes have been made to the guidelines compared to previously adopted guidelines.
Approval of the board of directors’ remuneration report
The AGM resolved to approve the remuneration report presented by the board of directors.
Authorization to issue new shares
The AGM resolved in accordance with the board of directors’ proposal to authorize the board of directors to issue new shares corresponding to not more than 20 per cent of the number of outstanding shares and votes at the time of the AGM.
CEO presentation for the Annual General Meeting 2022: https://tv.streamfabriken.com/vicore-pharma-inspelning-2022
Gothenburg, 11 May 2022
Vicore Pharma Holding AB (publ)
For further information, please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 70 975 98 63
Hans Jeppsson, CFO
Phone: +46 70 553 14 65
The information was submitted for publication, through the agency of the contact persons set out above, on 11 May 2022 at 10:30 CEST.Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)
Source: Vicore Pharma